Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer
W. Fraser Symmans(The University of Texas MD Anderson Cancer Center), Smita Asare(Quantum Leap Healthcare Collaborative), Andres Forero‐Torres(Kirklin Clinic), Sonal Shad(University of California, San Francisco), Barbara Haley(Shaanxi Research Association for Women and Family), Erin D. Ellis(University of Hawaii Cancer Center), Idris Tolgay Ocal(Mayo Clinic in Arizona), Lajos Pusztai(Yale University), Rashmi K. Murthy(The University of Texas MD Anderson Cancer Center), Minetta C. Liu(Mayo Clinic), Qamar J. Khan(University of Kansas Medical Center), Michael D. Feldman(University of Pennsylvania), Judy C. Boughey(Mayo Clinic in Arizona), Husain Sattar(University of Chicago), Julie E. Lang(University of Southern California), Brian Datnow(University of California, San Diego), Laila Khazai(Moffitt Cancer Center), Mara H. Rendi(University of Washington), Sunati Sahoo(The University of Texas Southwestern Medical Center), Kirsten K. Edmiston(Virginia Cancer Institute), Donald W. Northfelt(Mayo Clinic in Arizona), Barbara A. Parker(University of California San Diego), A. Jo Chien(University of California, San Francisco), Hyo S. Han(Moffitt Cancer Center), Kathy S. Albain(Loyola University Chicago), Sharon B. Sams(University of Colorado Denver), Christina Yau(Hospital Authority), Shi Wei(University of Alabama at Birmingham), Amy S. Clark(Abramson Center for Jewish Life), Rebecca K. Viscusi(University of Arizona), Jeffrey B. Matthews(University of California, San Francisco), Sara J. Venters(University of California, San Francisco), Brian Leyland‐Jones(Avera Health), Kathleen Kemmer(University of Michigan), Claudine Isaacs(Georgetown University), Megan L. Troxell(Stanford University), Ronald Balassanian, Beiyun Chen(Mayo Clinic), Jay Zeck(Georgetown University), Paulette Mhawech‐Fauceglia, Lauren LeBeau(University of Arizona), Anne M. Wallace(University of California San Diego), Anthony Elias(University of Colorado Cancer Center), Gregor Krings(Cleveland Clinic), Molly Klein(University of Minnesota), Tuyethoa N. Vinh(Inova Health System), Xiuzhen Duan(Loyola University Chicago), Fang Fan(South China Normal University), Yunn-Yi Chen(University of California, San Francisco), Rita Nanda(University of Chicago)
Cited by 110
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
|Cell|2018|2.8k
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
|Journal of Clinical Oncology|2007|1.6k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k